Calistoga Pharmaceuticals Announces Oral and Poster Presentations at American Society of Hematology Annual Meeting

SEATTLE--(BUSINESS WIRE)--Calistoga Pharmaceuticals, Inc., the leader in the development of delta-isoform-selective phosphatidylinositol 3-kinase (PI3K-delta) inhibitors for the treatment of cancer and inflammatory diseases, today announced the upcoming presentation of clinical and preclinical results supporting the clinical benefit of CAL-101, an oral, PI3K-delta inhibitor, in the treatment of patients with hematologic malignancies. The new data will be featured in two oral presentations and five poster presentations at the 52nd American Society of Hematology (ASH) Annual Meeting being held December 4-7, 2010 in Orlando, FL.